- Home
- RARE vs SYBT Comparison
RARE vs SYBT Comparison
Compare RARE & SYBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- SYBT
- Stock Information
- Founded
- RARE 2010
- SYBT 1904
- Country
- RARE United States
- SYBT United States
- Employees
- RARE N/A
- SYBT N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- SYBT Major Banks
- Sector
- RARE Health Care
- SYBT Finance
- Exchange
- RARE Nasdaq
- SYBT Nasdaq
- Market Cap
- RARE 3.0B
- SYBT 2.1B
- IPO Year
- RARE 2014
- SYBT N/A
- Fundamental
- Price
- RARE $32.62
- SYBT $66.58
- Analyst Decision
- RARE Strong Buy
- SYBT Hold
- Analyst Count
- RARE 14
- SYBT 3
- Target Price
- RARE $86.64
- SYBT $83.67
- AVG Volume (30 Days)
- RARE 1.6M
- SYBT 138.2K
- Earning Date
- RARE 11-04-2025
- SYBT 10-24-2025
- Dividend Yield
- RARE N/A
- SYBT 1.96%
- EPS Growth
- RARE N/A
- SYBT 22.18
- EPS
- RARE N/A
- SYBT 4.35
- Revenue
- RARE $610,159,000.00
- SYBT $364,546,000.00
- Revenue This Year
- RARE $19.72
- SYBT $16.83
- Revenue Next Year
- RARE $23.29
- SYBT $5.12
- P/E Ratio
- RARE N/A
- SYBT $14.98
- Revenue Growth
- RARE 26.77
- SYBT 11.32
- 52 Week Low
- RARE $25.81
- SYBT $60.75
- 52 Week High
- RARE $57.97
- SYBT $83.83
- Technical
- Relative Strength Index (RSI)
- RARE 57.75
- SYBT 37.82
- Support Level
- RARE $30.95
- SYBT $64.56
- Resistance Level
- RARE $34.50
- SYBT $71.16
- Average True Range (ATR)
- RARE 1.22
- SYBT 2.05
- MACD
- RARE 0.31
- SYBT -0.13
- Stochastic Oscillator
- RARE 59.23
- SYBT 29.94
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About SYBT Stock Yards Bancorp Inc.
Stock Yards Bancorp Inc operates as a bank. The bank has two reportable operating segments namely Commercial Banking and Wealth Management and Trust. Its services include loan and deposit services, cash management services, securities brokerage activities, mortgage origination, and others. It generates the majority of its revenue from the Commercial Banking segment.